PL354979A1 - Pochodne tetrahydrotiopiranoftalazynonu stanowiące inhibitory PDE4 - Google Patents

Pochodne tetrahydrotiopiranoftalazynonu stanowiące inhibitory PDE4

Info

Publication number
PL354979A1
PL354979A1 PL00354979A PL35497900A PL354979A1 PL 354979 A1 PL354979 A1 PL 354979A1 PL 00354979 A PL00354979 A PL 00354979A PL 35497900 A PL35497900 A PL 35497900A PL 354979 A1 PL354979 A1 PL 354979A1
Authority
PL
Poland
Prior art keywords
ranphthalazinone
tetrahydrothiopy
derivatives
pde4 inhibitors
pde4
Prior art date
Application number
PL00354979A
Other languages
English (en)
Inventor
Jan Geert Sterk
Armin Hatzelmann
Hans-Peter Kley
Daniela Bundschuh
Der Laan Ivonne Johanna Van
Hendrik Timmerman
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of PL354979A1 publication Critical patent/PL354979A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL00354979A 1999-10-25 2000-10-24 Pochodne tetrahydrotiopiranoftalazynonu stanowiące inhibitory PDE4 PL354979A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99121243 1999-10-25
US20395000P 2000-05-12 2000-05-12
PCT/EP2000/010445 WO2001030777A1 (en) 1999-10-25 2000-10-24 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors

Publications (1)

Publication Number Publication Date
PL354979A1 true PL354979A1 (pl) 2004-03-22

Family

ID=26153155

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00354979A PL354979A1 (pl) 1999-10-25 2000-10-24 Pochodne tetrahydrotiopiranoftalazynonu stanowiące inhibitory PDE4

Country Status (20)

Country Link
US (2) US6544993B1 (pl)
EP (1) EP1244654A1 (pl)
JP (1) JP2003512466A (pl)
KR (1) KR20020043238A (pl)
CN (1) CN1146562C (pl)
AU (1) AU781137B2 (pl)
BR (1) BR0014990A (pl)
CA (1) CA2388119A1 (pl)
CZ (1) CZ20021457A3 (pl)
EA (1) EA005856B1 (pl)
HK (1) HK1047276A1 (pl)
HR (1) HRP20020350A2 (pl)
HU (1) HUP0203487A2 (pl)
IL (1) IL148807A0 (pl)
MX (1) MXPA02003581A (pl)
NO (1) NO20021959L (pl)
PL (1) PL354979A1 (pl)
SK (1) SK7232002A3 (pl)
TR (1) TR200201128T2 (pl)
WO (1) WO2001030777A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005856B1 (ru) * 1999-10-25 2005-06-30 Алтана Фарма Аг Тетрагидротиопиранфталазиноновые производные в качестве ингибиторов pde4
KR20030074817A (ko) * 2001-02-15 2003-09-19 알타나 파마 아게 Ｐｄｅ4 억제제로서의 프탈라지논-피페리디노-유도체
KR20030089723A (ko) * 2001-04-25 2003-11-22 알타나 파마 아게 피페라지노-유도체 및 이것의 ｐｄｅ4 억제제로서의 용도
NZ529221A (en) * 2001-04-25 2005-04-29 Altana Pharma Ag Phthalazinones with PDE-inhibiting properties for treatment of airway disorders and other inflammatory conditions
TWI347845B (en) * 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
EP1542987A1 (en) * 2002-08-10 2005-06-22 ALTANA Pharma AG Piperidine-n-oxide-derivatives
AU2003255376A1 (en) * 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
EP1537100B1 (en) * 2002-08-10 2007-04-25 ALTANA Pharma AG Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
PL373146A1 (pl) * 2002-08-10 2005-08-22 Altana Pharma Ag Pochodne pirydazynonu jako inhibitory PDE4
EP1587512A2 (en) * 2003-01-14 2005-10-26 ALTANA Pharma AG Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
EP1716123A1 (en) * 2004-02-04 2006-11-02 Altana Pharma AG Pyridazinone derivatives and their use as pde4 inhibitors
JP4778449B2 (ja) * 2004-02-04 2011-09-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしての２−（ピペリジン−４−イル）−４，５−ジヒドロ−２ｈ−ピリダジン−３−オン誘導体
CN104803973A (zh) * 2004-03-03 2015-07-29 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
WO2012080735A1 (en) * 2010-12-16 2012-06-21 Convergence Pharmaceuticals Limited Ask1 inhibiting pyrrolopyrimidine derivatives
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9204808D0 (en) * 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
JP3100984B2 (ja) 1992-12-02 2000-10-23 ファイザー・インク． 選択的ｐｄｅ▲下ｉ▼▲下ｖ▼阻害物質としてのカテコールジエーテル類
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
PT971901E (pt) * 1997-01-15 2003-07-31 Altana Pharma Ag Ftalazinonas
US6380196B1 (en) 1997-12-15 2002-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihydrobenzofurans
AU1760399A (en) * 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
DE69918422T2 (de) 1998-03-14 2005-08-11 Altana Pharma Ag Phthalazinone als PDE3/4 Inhibitoren
EA005856B1 (ru) * 1999-10-25 2005-06-30 Алтана Фарма Аг Тетрагидротиопиранфталазиноновые производные в качестве ингибиторов pde4

Also Published As

Publication number Publication date
MXPA02003581A (es) 2002-10-23
HK1047276A1 (zh) 2003-02-14
SK7232002A3 (en) 2002-09-10
CA2388119A1 (en) 2001-05-03
US6544993B1 (en) 2003-04-08
EP1244654A1 (en) 2002-10-02
AU781137B2 (en) 2005-05-05
US20030166655A1 (en) 2003-09-04
KR20020043238A (ko) 2002-06-08
CN1146562C (zh) 2004-04-21
JP2003512466A (ja) 2003-04-02
BR0014990A (pt) 2002-06-18
CN1382137A (zh) 2002-11-27
IL148807A0 (en) 2002-09-12
NO20021959L (no) 2002-05-29
WO2001030777A1 (en) 2001-05-03
TR200201128T2 (tr) 2002-08-21
EA005856B1 (ru) 2005-06-30
EA200200381A1 (ru) 2002-10-31
HUP0203487A2 (hu) 2003-02-28
NO20021959D0 (no) 2002-04-25
AU1515101A (en) 2001-05-08
US6846821B2 (en) 2005-01-25
CZ20021457A3 (cs) 2002-07-17
HRP20020350A2 (en) 2004-02-29

Similar Documents

Publication Publication Date Title
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
HUP0202450A3 (en) N-heterocyclic derivatives as nos inhibitors
IL149034A0 (en) Quinazoline derivatives as vegf inhibitors
EG23817A (en) 4-Phenyl-pyridine derivatives
GB9900416D0 (en) Inhibitors
HUP0202713A3 (en) Pteridinones as kinase inhibitors
GC0000338A (en) 5-Phenyl-pyrimidine derivatives
PL355099A1 (pl) Pochodne pirolu jako inhibitory fosfodiesterazy VII
IL148058A0 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives
HK1044940A1 (zh) 異噁唑咪唑羧酰胺衍生物
PL354979A1 (pl) Pochodne tetrahydrotiopiranoftalazynonu stanowiące inhibitory PDE4
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
HK1042695A1 (zh) 蛋白酶抑制劑
GB9925880D0 (en) B-Carboline derivatives
HK1048638A1 (zh) Cyclopenteneone衍生物
HK1045987A1 (zh) 3-氨基-2-苄基-1-苯基-丙烷衍生物
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
AP2001002327A0 (en) 1-Trifluoromethyl-4-hydroxy-7- piperidinylaminomethy lchroman derivatives
AU2001240939A1 (en) Isoquinoline derivatives as pde4 inhibitors
ZA200203157B (en) Tetrahydrothiopy ranphthalazinone derivatives as PDE4 inhibitors.
GB9917294D0 (en) Inhibitors
GB9929341D0 (en) Inhibitors
GB9900413D0 (en) Inhibitors
GB9929340D0 (en) Inhibitors
GB9907134D0 (en) Antimor napthylcombretastatin derivatives

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)